Therefore, based on mentioned above data, we can postulate that our results are the first to provide the NLRP3 inflammasome in the hippocampus as a new, sensitive pharmacological target for antidepressant drugs with various mechanisms of action, i.e., tianeptine, venlafaxine, and fluoxetine, and suggest an interesting therapeutic strategy for the modulation and treatment of depression, which may be accompanied by improvements in the behavioral dysfunctions evoked by prenatal stress. Here, NLRP3 is linked to depressive disorder.